{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T01:17:57Z","timestamp":1789780677711,"version":"4.0.1"},"reference-count":196,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH\/NIAID","award":["R01 AI181600"],"award-info":[{"award-number":["R01 AI181600"]}]},{"name":"NIH\/NIGMS","award":["R35 GM151169"],"award-info":[{"award-number":["R35 GM151169"]}]},{"name":"UT Rising STARs award"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Viral fusion proteins are indispensable mediators of viral entry that orchestrate the fusion of viral and host membranes, making them primary targets for antiviral interventions. Class I fusion proteins, displayed on the surface of enveloped viruses (such as HIV-1, RSV, SARS-CoV-2, Nipah, influenza, and Ebola viruses), share conserved structural features, including the fusion peptide or loop and heptad repeat regions. These elements are essential for the formation of the post-fusion six-helix bundle during membrane fusion. Peptide inhibitors that mimic heptad repeat motifs have consequently emerged as an effective strategy for blocking the fusion process. This review summarizes design strategies for such inhibitors and highlights how sequence and structural insights have enabled their optimization via \u03b1-helical stabilization, hydrocarbon stapling, lactam bridges, lipid conjugation, macrocyclization, and multivalency. Using representative examples across major viral systems, this review illustrates how these strategies have led to the development of potent, stable, and even broad-spectrum antiviral peptides. This review provides insights to guide the rational design of next-generation peptide-based fusion inhibitors targeting viral membrane fusion.<\/jats:p>","DOI":"10.3390\/pathogens15010032","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:50:21Z","timestamp":1766710221000},"page":"32","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Structure-Guided Design of Peptide Inhibitors Targeting Class I Viral Fusion Proteins"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3327-0116","authenticated-orcid":false,"given":"Narendra Kumar","family":"Gonepudi","sequence":"first","affiliation":[{"name":"Department of Cellular and Molecular Biology, School of Medicine, University of Texas at Tyler Health Science Center, Tyler, TX 75708, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Baffour Awuah","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Biology, School of Medicine, University of Texas at Tyler Health Science Center, Tyler, TX 75708, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4452-9240","authenticated-orcid":false,"given":"Wang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Biology, School of Medicine, University of Texas at Tyler Health Science Center, Tyler, TX 75708, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3844-8797","authenticated-orcid":false,"given":"Revansiddha H.","family":"Katte","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Biology, School of Medicine, University of Texas at Tyler Health Science Center, Tyler, TX 75708, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maolin","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Biology, School of Medicine, University of Texas at Tyler Health Science Center, Tyler, TX 75708, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nsmb.1456","article-title":"Viral membrane fusion","volume":"15","author":"Harrison","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1016\/j.jmb.2018.06.024","article-title":"Virus-Receptor Interactions: The Key to Cellular Invasion","volume":"430","author":"Maginnis","year":"2018","journal-title":"J. Mol. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.cell.2018.02.054","article-title":"Common Features of Enveloped Viruses and Implications for Immunogen Design for Next-Generation Vaccines","volume":"172","author":"Rey","year":"2018","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.virol.2015.03.043","article-title":"Viral membrane fusion","volume":"479\u2013480","author":"Harrison","year":"2015","journal-title":"Virology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0092-8674(00)80205-6","article-title":"Core structure of gp41 from the HIV envelope glycoprotein","volume":"89","author":"Chan","year":"1997","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/289366a0","article-title":"Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution","volume":"289","author":"Wilson","year":"1981","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"R750","DOI":"10.1016\/j.cub.2020.05.029","article-title":"Virus and eukaryote fusogen superfamilies","volume":"30","author":"Vance","year":"2020","journal-title":"Curr. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Barrett, C.T., and Dutch, R.E. (2020). Viral Membrane Fusion and the Transmembrane Domain. Viruses, 12.","DOI":"10.3390\/v12070693"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ebel, H., Benecke, T., and Vollmer, B. (2022). Stabilisation of Viral Membrane Fusion Proteins in Prefusion Conformation by Structure-Based Design for Structure Determination and Vaccine Development. Viruses, 14.","DOI":"10.3390\/v14081816"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nsmb.1451","article-title":"Membrane fusion","volume":"15","author":"Wickner","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1023\/A:1010454803579","article-title":"Common properties of fusion peptides from diverse systems","volume":"20","author":"Martin","year":"2000","journal-title":"Biosci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-virology-111821-093413","article-title":"Viral Membrane Fusion: A Dance Between Proteins and Lipids","volume":"10","author":"White","year":"2023","journal-title":"Annu. Rev. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0092-8674(03)00112-0","article-title":"Membrane Fusion","volume":"112","author":"Jahn","year":"2003","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1146\/annurev.biochem.70.1.777","article-title":"Mechanisms of Viral Membrane Fusion and Its Inhibition","volume":"70","author":"Eckert","year":"2001","journal-title":"Annu. Rev. Biochem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.chom.2018.09.003","article-title":"Partially Open HIV-1 Envelope Structures Exhibit Conformational Changes Relevant for Coreceptor Binding and Fusion","volume":"24","author":"Wang","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7788","DOI":"10.1128\/JVI.00555-11","article-title":"Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes","volume":"85","author":"McLellan","year":"2011","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41586-023-06273-4","article-title":"Cryo-EM structure of SARS-CoV-2 postfusion spike in membrane","volume":"619","author":"Shi","year":"2023","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41586-020-2333-6","article-title":"Structural transitions in influenza haemagglutinin at membrane fusion pH","volume":"583","author":"Benton","year":"2020","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9288","DOI":"10.1073\/pnas.0503989102","article-title":"Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein","volume":"102","author":"Yin","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nature18615","article-title":"Toremifene interacts with and destabilizes the Ebola virus glycoprotein","volume":"535","author":"Zhao","year":"2016","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e01707-20","DOI":"10.1128\/JVI.01707-20","article-title":"Novel Roles of the N1 Loop and N4 Alpha-Helical Region of the Nipah Virus Fusion Glycoprotein in Modulating Early and Late Steps of the Membrane Fusion Cascade","volume":"95","author":"Zamora","year":"2021","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1073\/pnas.0400576101","article-title":"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides","volume":"101","author":"Bosch","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2174\/1570162X19666210908115231","article-title":"Peptide-based Fusion Inhibitors for Preventing the Six-helix Bundle Formation of Class I Fusion Proteins: HIV and Beyond","volume":"19","author":"Monteiro","year":"2021","journal-title":"Curr. HIV Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Lozada, C., Barlow, T.M.A., Gonzalez, S., Lubin-Germain, N., and Ballet, S. (2021). Identification and Characteristics of Fusion Peptides Derived From Enveloped Viruses. Front. Chem., 9.","DOI":"10.3389\/fchem.2021.689006"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2174\/1381612024607180","article-title":"Peptide and non-peptide HIV fusion inhibitors","volume":"8","author":"Jiang","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Duzgunes, N., Fernandez-Fuentes, N., and Konopka, K. (2021). Inhibition of Viral Membrane Fusion by Peptides and Approaches to Peptide Design. Pathogens, 10.","DOI":"10.3390\/pathogens10121599"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1146\/annurev-virology-022221-063725","article-title":"Small-Molecule Inhibition of Viral Fusion Glycoproteins","volume":"8","author":"Liu","year":"2021","journal-title":"Annu. Rev. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Liang, G., Huang, Y., Wang, J., Gao, X., Zhao, Y., Ga, L., Zhao, Y., Ma, Y., Xiao, Y., and Wang, T. (2025). Peptide-Based Fusion Inhibitors Targeting 6-HB: Resistance to HIV-1 outside of Cells. Antiretroviral Therapy\u2014Latest Advances and Perspectives [Working Title], IntechOpen.","DOI":"10.5772\/intechopen.1011082"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Nyanguile, O. (2019). Peptide Antiviral Strategies as an Alternative to Treat Lower Respiratory Viral Infections. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01366"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Tran, E.E., Borgnia, M.J., Kuybeda, O., Schauder, D.M., Bartesaghi, A., Frank, G.A., Sapiro, G., Milne, J.L., and Subramaniam, S. (2012). Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002797"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/s41467-024-45480-z","article-title":"A general computational design strategy for stabilizing viral class I fusion proteins","volume":"15","author":"Gonzalez","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"ref_33","first-page":"83","article-title":"Structure and function of respiratory syncytial virus surface glycoproteins","volume":"372","author":"McLellan","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1097-2765(00)80159-8","article-title":"Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain","volume":"2","author":"Weissenhorn","year":"1998","journal-title":"Mol. Cell"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Zhu, X., Mannar, D., Srivastava, S.S., Berezuk, A.M., Demers, J.P., Saville, J.W., Leopold, K., Li, W., Dimitrov, D.S., and Tuttle, K.S. (2021). Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies. PLoS Biol., 19.","DOI":"10.1371\/journal.pbio.3001237"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41467-022-28882-9","article-title":"Cryo-EM structure of a SARS-CoV-2 omicron spike protein ectodomain","volume":"13","author":"Ye","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1126\/science.1245627","article-title":"Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer","volume":"342","author":"Lyumkis","year":"2013","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41586-020-2665-2","article-title":"Structures and distributions of SARS-CoV-2 spike proteins on intact virions","volume":"588","author":"Ke","year":"2020","journal-title":"Nature"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9619","DOI":"10.1073\/pnas.1106536108","article-title":"Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers","volume":"108","author":"Swanson","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1016\/j.celrep.2020.03.025","article-title":"Structure-Based Design of Prefusion-Stabilized Filovirus Glycoprotein Trimers","volume":"30","author":"Rutten","year":"2020","journal-title":"Cell Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1556\/1886.2025.00017","article-title":"Structural biology of Nipah virus G and F glycoproteins: Insights into therapeutic and vaccine development","volume":"15","author":"Salleh","year":"2025","journal-title":"Eur. J. Microbiol. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"108056","DOI":"10.1016\/j.compbiomed.2024.108056","article-title":"Immunoinformatics-driven In silico vaccine design for Nipah virus (NPV): Integrating machine learning and computational epitope prediction","volume":"170","author":"Shahab","year":"2024","journal-title":"Comput. Biol. Med."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Son, A., Park, J., Kim, W., Lee, W., Yoon, Y., Ji, J., and Kim, H. (2024). Integrating Computational Design and Experimental Approaches for Next-Generation Biologics. Biomolecules, 14.","DOI":"10.20944\/preprints202407.1917.v1"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"eade6422","DOI":"10.1126\/scitranslmed.ade6422","article-title":"Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine","volume":"15","author":"Che","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"Science"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/s41467-023-37786-1","article-title":"High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike","volume":"14","author":"Tan","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ymthe.2024.02.011","article-title":"A potential bivalent mRNA vaccine candidate protects against both RSV and SARS-CoV-2 infections","volume":"32","author":"Wu","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1038\/s41467-024-48059-w","article-title":"Universal paramyxovirus vaccine design by stabilizing regions involved in structural transformation of the fusion protein","volume":"15","author":"Langedijk","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"eaay5051","DOI":"10.1126\/science.aay5051","article-title":"De novo protein design enables the precise induction of RSV-neutralizing antibodies","volume":"368","author":"Sesterhenn","year":"2020","journal-title":"Science"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e81167","DOI":"10.7554\/eLife.81167","article-title":"Revealing druggable cryptic pockets in the Nsp1 of SARS-CoV-2 and other beta-coronaviruses by simulations and crystallography","volume":"11","author":"Borsatto","year":"2022","journal-title":"eLife"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"bbad459","DOI":"10.1093\/bib\/bbad459","article-title":"Unraveling viral drug targets: A deep learning-based approach for the identification of potential binding sites","volume":"25","author":"Popov","year":"2023","journal-title":"Brief. Bioinform."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"105740","DOI":"10.1016\/j.antiviral.2023.105740","article-title":"Artificial intelligence: Machine learning approach for screening large database and drug discovery","volume":"220","author":"Parvatikar","year":"2023","journal-title":"Antivir. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/2211-5463.13908","article-title":"Viral entry mechanisms: The role of molecular simulation in unlocking a key step in viral infections","volume":"15","author":"Valerio","year":"2025","journal-title":"FEBS Open Bio"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.tibs.2024.06.012","article-title":"Visualizing intermediate stages of viral membrane fusion by cryo-electron tomography","volume":"49","author":"Kephart","year":"2024","journal-title":"Trends Biochem. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"42141","DOI":"10.1074\/jbc.M111.254243","article-title":"Capturing a fusion intermediate of influenza hemagglutinin with a cholesterol-conjugated peptide, a new antiviral strategy for influenza virus","volume":"286","author":"Lee","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"14064","DOI":"10.1021\/bi049101q","article-title":"Characterization of the heptad repeat regions, HR1 and HR2, and design of a fusion core structure model of the spike protein from severe acute respiratory syndrome (SARS) coronavirus","volume":"43","author":"Xu","year":"2004","journal-title":"Biochemistry"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Hashemi, Z.S., Zarei, M., Fath, M.K., Ganji, M., Farahani, M.S., Afsharnouri, F., Pourzardosht, N., Khalesi, B., Jahangiri, A., and Rahbar, M.R. (2021). In silico Approaches for the Design and Optimization of Interfering Peptides Against Protein-Protein Interactions. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.669431"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Le, K., Kannappan, S., Kim, T., Lee, J.H., Lee, H.R., and Kim, K.K. (2023). Structural understanding of SARS-CoV-2 virus entry to host cells. Front. Mol. Biosci., 10.","DOI":"10.3389\/fmolb.2023.1288686"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1038\/ncomms4067","article-title":"Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor","volume":"5","author":"Lu","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Benhaim, M.A., and Lee, K.K. (2020). New Biophysical Approaches Reveal the Dynamics and Mechanics of Type I Viral Fusion Machinery and Their Interplay with Membranes. Viruses, 12.","DOI":"10.3390\/v12040413"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America","volume":"348","author":"Lalezari","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"10537","DOI":"10.1073\/pnas.89.21.10537","article-title":"A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition","volume":"89","author":"Wild","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1089\/aid.1993.9.1051","article-title":"A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion","volume":"9","author":"Wild","year":"1993","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd1331","article-title":"Enfuvirtide: The first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes","volume":"3","author":"Matthews","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cell.2021.11.032","article-title":"Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide","volume":"185","author":"Xue","year":"2022","journal-title":"Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.csbj.2019.01.012","article-title":"Stapled Peptides Inhibitors: A New Window for Target Drug Discovery","volume":"17","author":"Ali","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/acschembio.3c00048","article-title":"Rapid Evaluation of Staple Placement in Stabilized alpha Helices Using Bacterial Surface Display","volume":"18","author":"Case","year":"2023","journal-title":"ACS Chem. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1038\/s41467-023-38039-x","article-title":"Engineering protein-based therapeutics through structural and chemical design","volume":"14","author":"Ebrahimi","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"101580","DOI":"10.1016\/j.nantod.2022.101580","article-title":"Multivalent ACE2 engineering-A promising pathway for advanced coronavirus nanomedicine development","volume":"46","author":"Obeng","year":"2022","journal-title":"Nano Today"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"8779","DOI":"10.1039\/D2RA07356K","article-title":"Dimerized fusion inhibitor peptides targeting the HR1-HR2 interaction of SARS-CoV-2","volume":"13","author":"Tsuji","year":"2023","journal-title":"RSC Adv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"13134","DOI":"10.1128\/JVI.02433-13","article-title":"Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus","volume":"87","author":"Gao","year":"2013","journal-title":"J. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.tim.2019.06.002","article-title":"Molecular Mechanism of HIV-1 Entry","volume":"27","author":"Chen","year":"2019","journal-title":"Trends Microbiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1016\/j.csbj.2024.11.020","article-title":"HIV-1-envelope trimer transitions from prefusion-closed to CD4-bound-open conformations through an occluded-intermediate state","volume":"23","author":"Lee","year":"2024","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Pu, J., Wang, Q., Xu, W., Lu, L., and Jiang, S. (2019). Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41. Viruses, 11.","DOI":"10.3390\/v11080705"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/00002030-199006000-00009","article-title":"Characterization of a putative cellular receptor for HIV-1 transmembrane glycoprotein using synthetic peptides","volume":"4","author":"Qureshi","year":"1990","journal-title":"AIDS"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/j.bbamem.2014.04.015","article-title":"Peptide entry inhibitors of enveloped viruses: The importance of interfacial hydrophobicity","volume":"1838","author":"Badani","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"103062","DOI":"10.1016\/j.jbc.2023.103062","article-title":"Structure-guided stabilization improves the ability of the HIV-1 gp41 hydrophobic pocket to elicit neutralizing antibodies","volume":"299","author":"Bruun","year":"2023","journal-title":"J. Biol. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"8578","DOI":"10.1128\/JVI.73.10.8578-8586.1999","article-title":"Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: Role of a conserved hydrophobic cavity in membrane fusion","volume":"73","author":"Ji","year":"1999","journal-title":"J. Virol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/387426a0","article-title":"Atomic structure of the ectodomain from HIV-1 gp41","volume":"387","author":"Weissenhorn","year":"1997","journal-title":"Nature"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"11259","DOI":"10.1074\/jbc.M411141200","article-title":"Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120","volume":"280","author":"Liu","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm1777","article-title":"Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs","volume":"14","author":"Shen","year":"2008","journal-title":"Nat. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"12428","DOI":"10.1128\/JVI.78.22.12428-12437.2004","article-title":"Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor","volume":"78","author":"Baldwin","year":"2004","journal-title":"J. Virol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"15613","DOI":"10.1073\/pnas.95.26.15613","article-title":"Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target","volume":"95","author":"Chan","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"10785","DOI":"10.1128\/JVI.05331-11","article-title":"Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function","volume":"85","author":"Eggink","year":"2011","journal-title":"J. Virol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Zhang, X., Zhu, Y., Hu, H., Zhang, S., Wang, P., Chong, H., He, J., Wang, X., and He, Y. (2018). Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket. Front. Cell. Infect. Microbiol., 8.","DOI":"10.3389\/fcimb.2018.00051"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1074\/jbc.RA118.001729","article-title":"Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus","volume":"293","author":"Zhu","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1128\/JVI.02524-07","article-title":"Mechanistic studies of a T20-dependent human immunodeficiency virus type 1 variant","volume":"82","author":"Baldwin","year":"2008","journal-title":"J. Virol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"14093","DOI":"10.1073\/pnas.1002713107","article-title":"Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic","volume":"107","author":"Bird","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3851\/IMP1930","article-title":"Novel HIV-1 Fusion Inhibition Peptides: Designing the Next Generation of Drugs","volume":"22","author":"Miyamoto","year":"2012","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"12772","DOI":"10.1073\/pnas.0701478104","article-title":"Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus","volume":"104","author":"Dwyer","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1128\/AAC.00976-09","article-title":"An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life","volume":"54","author":"Xie","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1021\/bi802303b","article-title":"Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation","volume":"48","author":"Liu","year":"2009","journal-title":"Biochemistry"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e01839-16","DOI":"10.1128\/JVI.01839-16","article-title":"A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus","volume":"91","author":"Xiong","year":"2017","journal-title":"J. Virol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1021\/acs.jmedchem.3c01543","article-title":"Antiviral Protein-Protein Interaction Inhibitors","volume":"67","author":"Markovic","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1742-4690-11-40","article-title":"Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK","volume":"11","author":"Chong","year":"2014","journal-title":"Retrovirology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"34558","DOI":"10.1074\/jbc.M112.390393","article-title":"The M-T hook structure is critical for design of HIV-1 fusion inhibitors","volume":"287","author":"Chong","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e01088-18","DOI":"10.1128\/JVI.01088-18","article-title":"Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus","volume":"92","author":"Chong","year":"2018","journal-title":"J. Virol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1073\/pnas.0901007106","article-title":"Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency","volume":"106","author":"Ingallinella","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Hollmann, A., Matos, P.M., Augusto, M.T., Castanho, M.A., and Santos, N.C. (2013). Conjugation of cholesterol to HIV-1 fusion inhibitor C34 increases peptide-membrane interactions potentiating its action. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060302"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"9447","DOI":"10.1038\/s41598-017-09230-0","article-title":"A first-in-human study of the novel HIV-fusion inhibitor C34-PEG(4)-Chol","volume":"7","author":"Quinn","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e02312-18","DOI":"10.1128\/JVI.02312-18","article-title":"Design and Characterization of Cholesterylated Peptide HIV-1\/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity","volume":"93","author":"Zhu","year":"2019","journal-title":"J. Virol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Wang, C., Cheng, S., Zhang, Y., Ding, Y., Chong, H., Xing, H., Jiang, S., Li, X., and Ma, L. (2019). Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action. Viruses, 11.","DOI":"10.3390\/v11090811"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"106190","DOI":"10.1016\/j.antiviral.2025.106190","article-title":"Structural characterization of HIV fusion inhibitor LP-98: Insights into antiviral and resistance mechanisms","volume":"239","author":"Liu","year":"2025","journal-title":"Antivir. Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e02018-24","DOI":"10.1128\/jvi.02018-24","article-title":"Addition of a short HIV-1 fusion-inhibitory peptide to PRO 140 antibody dramatically increases its antiviral breadth and potency","volume":"99","author":"Yan","year":"2025","journal-title":"J. Virol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1021\/acs.molpharmaceut.7b01004","article-title":"Pharmacokinetic and Chemical Synthesis Optimization of a Potent d-Peptide HIV Entry Inhibitor Suitable for Extended-Release Delivery","volume":"15","author":"Redman","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1006\/clim.2000.4896","article-title":"N36, a synthetic N-terminal heptad repeat domain of the HIV-1 envelope protein gp41, is an activator of human phagocytes","volume":"96","author":"Le","year":"2000","journal-title":"Clin. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"14238","DOI":"10.1074\/jbc.M201453200","article-title":"Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41","volume":"277","author":"Bewley","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"BSR20192196","DOI":"10.1042\/BSR20192196","article-title":"Trimeric heptad repeat synthetic peptides HR1 and HR2 efficiently inhibit HIV-1 entry","volume":"39","author":"Mzoughi","year":"2019","journal-title":"Biosci. Rep."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1073\/pnas.201392898","article-title":"Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region","volume":"98","author":"Eckert","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/nsb1295-1075","article-title":"A trimeric structural domain of the HIV-1 transmembrane glycoprotein","volume":"2","author":"Lu","year":"1995","journal-title":"Nat. Struct. Biol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/07391102.1997.10508958","article-title":"A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein","volume":"15","author":"Lu","year":"1997","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"13697","DOI":"10.1021\/bi9606962","article-title":"HIV-1 membrane fusion mechanism: Structural studies of the interactions between biologically-active peptides from gp41","volume":"35","author":"Lawless","year":"1996","journal-title":"Biochemistry"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1128\/JVI.02546-06","article-title":"Human Immunodeficiency Virus Type 1 Variants Resistant to First- and Second-Version Fusion Inhibitors and Cytopathic in Ex Vivo Human Lymphoid Tissue","volume":"81","author":"Chinnadurai","year":"2007","journal-title":"J. Virol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1128\/JVI.00373-15","article-title":"Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket","volume":"89","author":"Su","year":"2015","journal-title":"J. Virol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e01323-17","DOI":"10.1128\/JVI.01323-17","article-title":"The Heptad Repeat C Domain of the Respiratory Syncytial Virus Fusion Protein Plays a Key Role in Membrane Fusion","volume":"92","author":"Bermingham","year":"2018","journal-title":"J. Virol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1083\/jcb.151.2.413","article-title":"Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion","volume":"151","author":"Melikyan","year":"2000","journal-title":"J. Cell Biol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1128\/JVI.74.13.5911-5920.2000","article-title":"The core of the respiratory syncytial virus fusion protein is a trimeric coiled coil","volume":"74","author":"Matthews","year":"2000","journal-title":"J. Virol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41579-019-0149-x","article-title":"Respiratory syncytial virus entry and how to block it","volume":"17","author":"Battles","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0006-291X(03)00197-9","article-title":"Both heptad repeats of human respiratory syncytial virus fusion protein are potent inhibitors of viral fusion","volume":"302","author":"Wang","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Patel, N., Tian, J.H., Flores, R., Jacobson, K., Walker, M., Portnoff, A., Gueber-Xabier, M., Massare, M.J., Glenn, G., and Ellingsworth, L. (2020). Flexible RSV Prefusogenic Fusion Glycoprotein Exposes Multiple Neutralizing Epitopes that May Collectively Contribute to Protective Immunity. Vaccines, 8.","DOI":"10.1101\/2020.09.14.296350"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/v5010211","article-title":"Respiratory syncytial virus entry inhibitors targeting the F protein","volume":"5","author":"Sun","year":"2013","journal-title":"Viruses"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1073\/pnas.93.5.2186","article-title":"Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion","volume":"93","author":"Lambert","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.1128\/JVI.77.9.5054-5064.2003","article-title":"Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein","volume":"77","author":"Douglas","year":"2003","journal-title":"J. Virol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ab.2010.10.020","article-title":"A fluorescence polarization assay using an engineered human respiratory syncytial virus F protein as a direct screening platform","volume":"409","author":"Park","year":"2011","journal-title":"Anal. Biochem."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1177\/135965350501000707","article-title":"Design and characterization of human respiratory syncytial virus entry inhibitors","volume":"10","author":"Ni","year":"2005","journal-title":"Antivir. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"7970","DOI":"10.1128\/JVI.00447-10","article-title":"Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein","volume":"84","author":"Magro","year":"2010","journal-title":"J. Virol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Lee, Y.Z., Han, J., Zhang, Y.N., Ward, G., Gomes, K.B., Auclair, S., Stanfield, R.L., He, L., Wilson, I.A., and Zhu, J. (2024). A tale of two fusion proteins: Understanding the metastability of human respiratory syncytial virus and metapneumovirus and implications for rational design of uncleaved prefusion-closed trimers. bioRxiv.","DOI":"10.1101\/2024.03.07.583986"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1021\/ja000563a","article-title":"An All-Hydrocarbon Cross-Linking System for Enhancing the Helicity and Metabolic Stability of Peptides","volume":"122","author":"Schafmeister","year":"2000","journal-title":"J. Am. Chem. Soc."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1172\/JCI75797","article-title":"Repurposing staples for viruses: Applying peptide design to RSV prophylaxis","volume":"124","author":"Katen","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1172\/JCI71856","article-title":"Mucosal delivery of a double-stapled RSV peptide prevents nasopulmonary infection","volume":"124","author":"Bird","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e02241-16","DOI":"10.1128\/AAC.02241-16","article-title":"A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading","volume":"61","author":"Gaillard","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e0138524","DOI":"10.1128\/mbio.01385-24","article-title":"A new mechanism of respiratory syncytial virus entry inhibition by small-molecule to overcome K394R-associated resistance","volume":"15","author":"Song","year":"2024","journal-title":"mBio"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Katte, R.H., Ao, Y., Xu, W., Han, Y., Zhong, G., Ghimire, D., Florence, J., Tucker, T.A., and Lu, M. (2024). Differentiating Cell Entry Potentials of SARS-CoV-2 Omicron Subvariants on Human Lung Epithelium Cells. Viruses, 16.","DOI":"10.3390\/v16030391"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41467-024-45404-x","article-title":"Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge","volume":"15","author":"Hsieh","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41392-021-00712-2","article-title":"Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation","volume":"6","author":"Xia","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e00635-20","DOI":"10.1128\/JVI.00635-20","article-title":"Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity","volume":"94","author":"Zhu","year":"2020","journal-title":"J. Virol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.virol.2017.07.033","article-title":"Lipidation increases antiviral activities of coronavirus fusion-inhibiting peptides","volume":"511","author":"Park","year":"2017","journal-title":"Virology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bsheal.2025.01.001","article-title":"Computational optimization of a pan-coronavirus fusion inhibitory peptide targeting spike\u2019s heptapeptide repeat region","volume":"7","author":"Gao","year":"2025","journal-title":"Biosaf. Health"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1002\/mco2.666","article-title":"Development of potent pan-coronavirus fusion inhibitors with a new design strategy","volume":"5","author":"Zhu","year":"2024","journal-title":"MedComm"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"106154","DOI":"10.1016\/j.antiviral.2025.106154","article-title":"Comprehensive preclinical characterization of IPB29, a pan-coronavirus fusion inhibitor under clinical trials","volume":"237","author":"Zhu","year":"2025","journal-title":"Antivir. Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1126\/science.abf4896","article-title":"Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets","volume":"371","author":"Schmitz","year":"2021","journal-title":"Science"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e0124922","DOI":"10.1128\/mbio.01249-22","article-title":"Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern","volume":"13","author":"Schmitz","year":"2022","journal-title":"mBio"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"18625","DOI":"10.1021\/acs.jmedchem.5c01614","article-title":"Potent Inhibition of Human Betacoronaviruses by a Short Double-Stapled Peptide Mimicking the HR2 Core Region in Viral Spike Protein","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"105571","DOI":"10.1016\/j.antiviral.2023.105571","article-title":"Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides","volume":"212","author":"Hu","year":"2023","journal-title":"Antivir. Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e2119467119","DOI":"10.1073\/pnas.2119467119","article-title":"Structural conservation among variants of the SARS-CoV-2 spike postfusion bundle","volume":"119","author":"Yang","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e0228924","DOI":"10.1128\/jvi.02289-24","article-title":"Research strategies of the N-peptide fusion inhibitor: A promising direction for discovering novel antivirals","volume":"99","author":"Huang","year":"2025","journal-title":"J. Virol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41467-023-44361-1","article-title":"A stapled lipopeptide platform for preventing and treating highly pathogenic viruses of pandemic potential","volume":"15","author":"Bird","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1021\/acscentsci.3c00313","article-title":"An HR2-Mimicking Sulfonyl-gamma-AApeptide Is a Potent Pan-coronavirus Fusion Inhibitor with Strong Blood-Brain Barrier Permeability, Long Half-Life, and Promising Oral Bioavailability","volume":"9","author":"Xue","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1038\/s41467-025-62214-x","article-title":"The efficacy and safety of inhaled peptide YKYY017 for COVID-19 patients with mild illness: A phase 2 randomized controlled trial","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"199170","DOI":"10.1016\/j.virusres.2023.199170","article-title":"SARS-CoV-2 inhibitory activity of a short peptide derived from internal fusion peptide of S2 subunit of spike glycoprotein","volume":"334","author":"Stincarelli","year":"2023","journal-title":"Virus Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"D49","DOI":"10.1016\/j.vaccine.2008.07.039","article-title":"The biology of influenza viruses","volume":"26","author":"Bouvier","year":"2008","journal-title":"Vaccine"},{"key":"ref_155","unstructured":"Boktor, S.W., Hafner, J.W., and Doerr, C. (2025). Influenza (Nursing). StatPearls, StatPearls Publishing."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3390\/v4071144","article-title":"Influenza virus-mediated membrane fusion: Determinants of hemagglutinin fusogenic activity and experimental approaches for assessing virus fusion","volume":"4","author":"Hamilton","year":"2012","journal-title":"Viruses"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2222\/jsv.59.205","article-title":"Entry process of enveloped viruses to host cells","volume":"59","author":"Miyauchi","year":"2009","journal-title":"Uirusu"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.bbamem.2013.10.004","article-title":"Receptor binding and pH stability\u2014How influenza A virus hemagglutinin affects host-specific virus infection","volume":"1838","author":"Mair","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s10930-020-09930-z","article-title":"Influenza Hemagglutinin Head Domain Mimicry by Rational Design","volume":"39","author":"Mallajosyula","year":"2020","journal-title":"Protein J."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Agamennone, M., Fantacuzzi, M., Vivenzio, G., Scala, M.C., Campiglia, P., Superti, F., and Sala, M. (2022). Antiviral Peptides as Anti-Influenza Agents. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911433"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"9223","DOI":"10.1128\/JVI.01153-13","article-title":"A Cholesterol Tag at the N Terminus of the Relatively Broad-Spectrum Fusion Inhibitory Peptide Targets an Earlier Stage of Fusion Glycoprotein Activation and Increases the Peptide\u2019s Antiviral Potency In Vivo","volume":"87","author":"Li","year":"2013","journal-title":"J. Virol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"183762","DOI":"10.1016\/j.bbamem.2021.183762","article-title":"The pH-sensitive action of cholesterol-conjugated peptide inhibitors of influenza virus","volume":"1863","author":"Silva","year":"2021","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"22790","DOI":"10.1038\/srep22790","article-title":"A \u201cbuilding block\u201d approach to the new influenza A virus entry inhibitors with reduced cellular toxicities","volume":"6","author":"Lin","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1021\/acs.bioconjchem.1c00258","article-title":"Lipopeptides for Vaccine Development","volume":"32","author":"Hamley","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1021\/acs.bioconjchem.8b00527","article-title":"Effective in Vivo Targeting of Influenza Virus through a Cell-Penetrating\/Fusion Inhibitor Tandem Peptide Anchored to the Plasma Membrane","volume":"29","author":"Figueira","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1126\/science.aan0516","article-title":"Potent peptidic fusion inhibitors of influenza virus","volume":"358","author":"Kadam","year":"2017","journal-title":"Science"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00726-020-02890-9","article-title":"Impact of non-proteinogenic amino acids in the discovery and development of peptide therapeutics","volume":"52","author":"Ding","year":"2020","journal-title":"Amino Acids"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"10083","DOI":"10.1039\/D1SC02562G","article-title":"Combining flavin photocatalysis with parallel synthesis: A general platform to optimize peptides with non-proteinogenic amino acids","volume":"12","author":"Immel","year":"2021","journal-title":"Chem. Sci."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1038\/s41467-021-22964-w","article-title":"Macrocyclic peptides exhibit antiviral effects against influenza virus HA and prevent pneumonia in animal models","volume":"12","author":"Saito","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e2426554122","DOI":"10.1073\/pnas.2426554122","article-title":"De novo design of D-peptide ligands: Application to influenza virus hemagglutinin","volume":"122","author":"Juraszek","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.immuni.2017.03.018","article-title":"An Amphibian Host Defense Peptide Is Virucidal for Human H1 Hemagglutinin-Bearing Influenza Viruses","volume":"46","author":"Holthausen","year":"2017","journal-title":"Immunity"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1080\/22221751.2022.2051753","article-title":"Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants","volume":"11","author":"Zhao","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coviro.2014.01.005","article-title":"Activation of paramyxovirus membrane fusion and virus entry","volume":"5","author":"Jardetzky","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1743-422X-2-57","article-title":"Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein","volume":"2","author":"Bossart","year":"2005","journal-title":"Virol. J."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3390\/v4020280","article-title":"Henipavirus mediated membrane fusion, virus entry and targeted therapeutics","volume":"4","author":"Steffen","year":"2012","journal-title":"Viruses"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Porotto, M., Rockx, B., Yokoyama, C.C., Talekar, A., Devito, I., Palermo, L.M., Liu, J., Cortese, R., Lu, M., and Feldmann, H. (2010). Inhibition of Nipah virus infection in vivo: Targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1001168"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/infdis\/jiy152","article-title":"Fusion Inhibitory Lipopeptides Engineered for Prophylaxis of Nipah Virus in Primates","volume":"218","author":"Mathieu","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Marques, M.C., Lousa, D., Silva, P.M., Faustino, A.F., Soares, C.M., and Santos, N.C. (2022). The Importance of Lipid Conjugation on Anti-Fusion Peptides against Nipah Virus. Biomedicines, 10.","DOI":"10.3390\/biomedicines10030703"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1128\/JVI.80.6.2815-2822.2006","article-title":"Detection of cell-cell fusion mediated by Ebola virus glycoproteins","volume":"80","author":"Bar","year":"2006","journal-title":"J. Virol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"5762","DOI":"10.1073\/pnas.95.10.5762","article-title":"Processing of the Ebola virus glycoprotein by the proprotein convertase furin","volume":"95","author":"Volchkov","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"15854","DOI":"10.1074\/jbc.M110.207084","article-title":"Inhibition of Ebola virus entry by a C-peptide targeted to endosomes","volume":"286","author":"Miller","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1110656","article-title":"Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection","volume":"308","author":"Chandran","year":"2005","journal-title":"Science"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nature10380","article-title":"Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection","volume":"477","author":"Cote","year":"2011","journal-title":"Nature"},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Saeed, M.F., Kolokoltsov, A.A., Albrecht, T., and Davey, R.A. (2010). Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1001110"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature07082","article-title":"Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor","volume":"454","author":"Lee","year":"2008","journal-title":"Nature"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"10194","DOI":"10.1128\/JVI.74.21.10194-10201.2000","article-title":"Functional importance of the coiled-coil of the Ebola virus glycoprotein","volume":"74","author":"Watanabe","year":"2000","journal-title":"J. Virol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1016\/j.bmcl.2013.07.056","article-title":"C-peptide inhibitors of Ebola virus glycoprotein-mediated cell entry: Effects of conjugation to cholesterol and side chain-side chain crosslinking","volume":"23","author":"Higgins","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/psc.2706","article-title":"Cholesterol-conjugated peptide antivirals: A path to a rapid response to emerging viral diseases","volume":"21","author":"Pessi","year":"2015","journal-title":"J. Pept. Sci."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"104592","DOI":"10.1016\/j.antiviral.2019.104592","article-title":"Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo","volume":"171","author":"Pessi","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/pro.2578","article-title":"Design and characterization of ebolavirus GP prehairpin intermediate mimics as drug targets","volume":"24","author":"Clinton","year":"2015","journal-title":"Protein Sci."},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Fan, L., Hu, Y., Li, R., Ding, J., Liu, Y., Yu, S., Hu, M., Su, R., Li, Y., and Yu, A. (2024). Enhanced immune reconstitution with albuvirtide in HIV-infected immunological non-responders. Front. Cell. Infect. Microbiol., 14.","DOI":"10.3389\/fcimb.2024.1397743"},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Angell, Y.M., Hartsock, W.J., and Reichart, T.M. (2022). Albuvirtide (Aikening), A gp41 Analog as an HIV-1 Fusion Inhibitor. Current Drug Synthesis, Wiley-Blackwell.","DOI":"10.1002\/9781119847281.ch6"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.hlife.2023.10.002","article-title":"Efficient inhibition of SARS-CoV-2 emerging EG.5, EG.5.1 and BA.2.86 variants by fusion inhibitor HY3000 peptide","volume":"2","author":"Wu","year":"2024","journal-title":"hLife"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1021\/bi901915g","article-title":"Origins of resistance to the HIVgp41 viral entry inhibitor T20","volume":"49","author":"McGillick","year":"2010","journal-title":"Biochemistry"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"30376","DOI":"10.1074\/jbc.M804672200","article-title":"Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors","volume":"283","author":"Qi","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"100228","DOI":"10.1016\/j.crphar.2025.100228","article-title":"Harnessing Antiviral Peptides: From Molecular Mechanisms to Clinical Translation","volume":"9","author":"Raj","year":"2025","journal-title":"Curr. Res. Pharmacol. Drug Discov."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/1\/32\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T01:07:12Z","timestamp":1766711232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/1\/32"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":196,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["pathogens15010032"],"URL":"https:\/\/doi.org\/10.3390\/pathogens15010032","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,25]]}}}